jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Both FT - Medium Biopsy 1-3 cm

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Biopsy from both fallopian tubes.

₹370₹529

30% OFF

Both FT - Medium Biopsy 1-3 cm

  • Why is it done?
    • To obtain tissue samples from breast lesions measuring 1-3 cm in size for microscopic examination and histopathological diagnosis
    • To differentiate between benign and malignant breast lesions, including fibroadenomas, cysts, papillomas, and carcinomas
    • To provide definitive diagnosis when imaging findings (mammography, ultrasound, MRI) show suspicious or indeterminate lesions
    • To evaluate breast masses that are palpable or detected on imaging requiring tissue characterization
    • Typically performed when imaging shows BI-RADS 3-5 lesions (probably benign through highly suspicious for malignancy)
  • Normal Range
    • Normal/Benign findings: Absence of malignant cells or atypical features; presence of normal adipose tissue, fibrous tissue, and normal glandular elements
    • Results are reported as categorical diagnoses based on histopathology rather than numerical values
    • Benign conditions may include: fibroadenoma, fat necrosis, cyst, papilloma, phyllodes tumor (benign), fibrocystic changes, or duct ectasia
    • Abnormal findings: Presence of malignant cells including ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), or other malignancies
    • Lesion size specification (1-3 cm) indicates medium-sized lesions optimal for this biopsy technique
  • Interpretation
    • Benign diagnosis: Indicates a non-cancerous lesion; typically requires no further biopsy; routine follow-up imaging as recommended by radiologist
    • Malignant diagnosis: Confirms cancer; requires immediate referral to oncology for staging and treatment planning
    • Atypia/Borderline findings: Presence of atypical cells that may require excisional biopsy for definitive diagnosis
    • Concordance assessment: Comparison of biopsy findings with imaging characteristics; discordant results may indicate need for repeat biopsy or surgical excision
    • Specimen adequacy: Results should specify if adequate tissue was obtained; insufficient material may necessitate repeat biopsy
    • Additional testing: Immunohistochemical stains (ER, PR, HER2) performed if malignancy detected to guide treatment decisions
    • Factors affecting interpretation: Specimen quality, adequacy of sampling, presence of artifact, patient age, hormonal status, and prior breast history
  • Associated Organs
    • Primary organ: Breast tissue (mammary gland) including ductal and lobular epithelium, stroma, and surrounding fat
    • Common benign conditions diagnosed: Fibroadenoma, lipoma, phyllodes tumor (benign), papillary lesions, complex cysts, and fibrocystic disease
    • Malignancies detected: Invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), ductal carcinoma in situ (DCIS), inflammatory breast cancer, triple-negative breast cancer
    • Potential complications: Minor bleeding (usually self-limited), bruising, infection (rare), hematoma formation, and nipple discharge
    • Systemic implications: Malignant findings may indicate metastatic potential requiring staging investigations including imaging of chest, liver, and bones
    • Axillary lymph node involvement: Cancer diagnosis warrants assessment of regional lymph nodes for staging purposes
  • Follow-up Tests
    • If benign diagnosis: Follow-up mammography or ultrasound in 6 months, then annually per ACR/SBI guidelines; consider MRI if high-risk lesion
    • If malignancy confirmed: Immunohistochemical studies (ER, PR, HER2, Ki-67) for prognostic and predictive information
    • Staging investigations: CT chest/abdomen/pelvis, bone scan, or PET-CT depending on tumor characteristics and grade
    • Genetic testing: Consider BRCA1/BRCA2 testing if applicable based on age, family history, or tumor characteristics
    • Surgical consultation: Oncologic surgery referral for treatment planning in confirmed malignancy cases
    • Excisional biopsy: May be recommended if atypia or discordant findings present with imaging
    • Repeat biopsy: If specimen inadequate or non-diagnostic, re-biopsy required for definitive diagnosis
    • Clinical follow-up: Physical examination and imaging at intervals determined by diagnosis and clinical risk stratification
  • Fasting Required?
    • Fasting requirement: No
    • Patient preparation: No fasting or dietary restrictions required prior to biopsy
    • Medication instructions: Continue all regular medications unless specifically instructed otherwise by physician
    • Anticoagulant management: Patients on aspirin, ibuprofen, or warfarin should discuss with physician; may need to discontinue 5-7 days prior
    • Clothing: Wear comfortable, easily removable clothing to allow access to breast
    • Scheduling: Best performed 7-14 days after menstrual period onset when breast tissue is less congested
    • Arrival time: Arrive 15 minutes early to complete informed consent and pre-procedure verification
    • Post-procedure care: Mild discomfort is normal; ice pack and acetaminophen may be used; avoid strenuous activity for 48 hours

How our test process works!

customers
customers